ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Interview

Japan's Daiichi Sankyo to make mRNA vaccine pillar of business

CEO hints at using technology for applications other than COVID-19

Daiichi Sankyo CEO Sunao Manabe said, "We are directing all available resources" to the development of the COVID vaccine. (Source photos by Kai Fujii and Kaisuke Ota) 

TOKYO -- Japanese drugmaker Daiichi Sankyo is racing to develop Japan's own messenger RNA vaccine, aiming for release by the end of next year, as CEO Sunao Manabe looks beyond COVID to make the technology a pillar of the company's future business.

"We are directing all available resources" to the development of the COVID vaccine, Manabe said in an interview with Nikkei Asia. "We are hurrying. We want to make the vaccine available to people as early as possible."

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more